Total: $62.3M Year to Date: $119.05M Company (Location) Partner (Location) Amt. (M) Details Date Genmab A/S (Copenhagen, Denmark) GlaxoSmithKline plc (London) DKK20 ($3.5) For the Japanese approval of Arzerra for use in patients with relapsed/refractory CD20-positive chronic lymphocytic leukemia 3/26/13 PolyTherics Ltd. (London) Celtic Pharma Holdings LP (London) ND For further progress on their hematology alliance to produce longer-acting versions of blood factor proteins 3/8/13 Receptos
A trained pathologist, Macartney also spent nearly 20 years at GlaxoSmithKline plc, moving up to senior vice president of global product strategy and project/portfolio management
By Marie Powers | BioWorld Today | Monday, April 8, 2013
GSK Biologicals, the vaccines arm of London-based GlaxoSmithKline plc, licensed the same technology for a HIV vaccine development project several years back
By Cormac Sheridan | BioWorld International | Wednesday, April 3, 2013
GlaxoSmithKline plc, of London, and the Texas A&M University System said the Department of Health and Human Services approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor for the Center for Innovation in Advanced Development and Manufacturing in Bryan-College Station, Texas
The drug went on to gain FDA approval as Vascepa, going head-to-head in the market with London-based GlaxoSmithKline plc's Lovaza (omega-3-acid ethyl esters). (See BioWorld Today, April 20, 2011, and Dec. 10, 2012.) The second IPO-seeker to set terms, Chimerix Inc., of Research Triangle Park, N.C., has brought forth impressive results in Phase II trials with its antiviral CMX001
By Randy Osborne | BioWorld Today | Tuesday, April 2, 2013
GSK Biologicals, the vaccines arm of London-based GlaxoSmithKline plc, licensed the same technology for a HIV vaccine development project several years back
By Cormac Sheridan | BioWorld Today | Monday, April 1, 2013
The funds had been held in escrow following the July 2012 sale of Welichem's development and commercialization rights to WBI-1001 outside the four territories to Stiefel Laboratories Inc., part of London-based GlaxoSmithKline plc (GSK
GlaxoSmithKline plc, of London, recently agreed to a nonexclusive material transfer, patent and know-how license deal with the Health Protection Agency (HPA) for the development and manufacture of a next-generation polio vaccine
FP-1039 is partnered with GlaxoSmithKline plc, which has the rights to develop and commercialize the molecule in the U.S., the European Union and Canada
By Anette Breindl | BioWorld Today | Thursday, March 28, 2013
Genmab A/S, of Copenhagen, Denmark, and GlaxoSmithKline plc, of London, said Japanese regulators approved Arzerra (ofatumumab) for use in patients with relapsed/refractory CD20-positive chronic lymphocytic leukemia
BioWorld International | Wednesday, March 27, 2013
GlaxoSmithKline plc, of London, and the Texas A&M University System said the Department of Health and Human Services approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor for the Center for Innovation in Advanced Development and Manufacturing in Bryan-College Station, Texas
Genmab A/S, of Copenhagen, Denmark, and GlaxoSmithKline plc, of London, said Japanese regulators approved Arzerra (ofatumumab) for use in patients with relapsed/refractory CD20-positive chronic lymphocytic leukemia
Meanwhile, CRLX101 also is in a 112-patient, Phase II, relapsed small-cell lung cancer (SCLC) trial, comparing the drug with topotecan (Hycamtin, GlaxoSmithKline plc), the only compound approved for second-line SCLC, which "tells you how difficult that disease is to treat," Fetzer said
By Randy Osborne | BioWorld Today | Monday, March 25, 2013
From the initial establishment of a link between caloric restriction, lifespan and sirtuins, in 2003, it took a mere five years for GlaxoSmithKline plc to acquire Sirtris Inc., which was founded in 2004 (Sinclair is a co-founder) to commercialize those discoveries, for more than $700 million. (See BioWorld Today, April 24, 2008.) But drugs based on sirtuins have not progressed through the pipeline apace
By Anette Breindl | BioWorld Insight | Monday, March 18, 2013
has raised £4 million (US$5.8 million) in seed financing from the GlaxoSmithKline plc venture fund SR One, enabling the company to further develop its platform technology for screening for small molecules that promote the differentiation of endogenous adult stem cells
By Nuala Moran | BioWorld International | Wednesday, March 13, 2013
GlaxoSmithKline plc (London) Trametinib Monotherapy Unresectable or metastatic melanoma Submitted an MAA to the EMA for its use as a monotherapy and in combination with dabrafenib 2/8/13 Janssen Research & Development LLC (Titusville, N.J.) Zytiga Abiraterone acetate Metastatic castration-resistant prostate cancer Phase III data of Zytiga plus prednisone showed it continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone 2/14/13
and its partner GlaxoSmithKline plc, of London, shouldn't have too much longer to wait for what is predicted to be a positive review from the PADAC for their once-daily inhaled corticosteroid
By Peter Winter | BioWorld Insight | Monday, March 11, 2013
Total: $62.3M Year to Date: $119.05M Company (Location) Partner (Location) Amt. (M) Details Date Genmab A/S (Copenhagen, Denmark) GlaxoSmithKline plc (London) DKK20 ($3.5) For the Japanese approval of Arzerra for use in patients with relapsed/refractory CD20-positive chronic lymphocytic leukemia 3/26/13 PolyTherics Ltd. (London) Celtic Pharma Holdings LP (London) ND For further progress on their hematology alliance to produce longer-acting versions of blood factor proteins 3/8/13 Receptos